

ASX RELEASE | OSTEOPORE LIMITED

## **Osteopore executes Memorandum of Co-operation and secures first orders with Boao Yiling Life Care Centre, China.**

### **Highlights**

- Osteopore executes Memorandum of Co-operation with Boao Yiling Life Care Centre in Hainan Province, China, and secures initial purchase contract for Osteopore products to be used in rhinoplasty surgery.
- Osteopore and Boao Yiling will co-operate to gain National Medical Products Administration (NMPA) approval for Osteopore products in rhinoplasty as well as other therapeutic areas.
- Initial purchase order from Sinopharm Group, a Chinese Government medical purchasing arm, for units to be used in initial trials for the purposes of training and generating data for NMPA registration.
- The agreement provides Osteopore with an initial market entry and reference site in China, and is a valuable step in securing clinical data and accelerating the company's future regulatory submission to the Chinese FDA.
- Osteopore's aesthetic products will primarily be used for bone reconstruction following facial cosmetic surgery. Boao Yiling and Sinopharm Group will provide training and support the utilisation of the implants.
- Boao Yiling Hospital is located in the Hainan Boao Le Cheng Medical Pioneer District, in Hainan province, China.

**19 November 2019: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company")**, a revenue generating medical technology company that has commercialised a range of patented 3D printed bioresorbable products, specifically engineered to facilitate natural bone healing, is pleased to announce a Memorandum of Co-Operation (MoC) with Boao Yiling Life Care Centre ("Boao Yiling") in Hainan province, China. The agreement will see both companies co-operate on developing rhinoplasty procedures and securing National Medical Products Administration (NMPA) registration for Osteopore's products in China.

Under the terms of the MoC, Osteopore and Boao Yiling will co-operate to create an international platform for leading medical technologies and products. Boao Yiling will assist with entry of Osteopore's products into the Chinese market, including collecting clinical data for NMPA registration. Osteopore and Boao Yiling will also jointly establish a rhinoplasty forum and work to introduce top global experts to the forum each year, and work together to establish a training base for using Osteopore's products in rhinoplasty.

In conjunction with the MoC, Osteopore has also secured an initial purchase order for product through Sinopharm Group (a Chinese government medical purchasing arm), who has provided a contract to buy Osteopore products for use in Boao Yiling. Products are provided to Sinopharm at commercial rates, in line with distributor prices in other jurisdictions. The revenue from sales under this initial purchase order are not considered material, however under the terms of the MoC with Boao Yiling,

data obtained from procedures will also become a valuable element for Osteopore's future submission to the NMPA.

Boao Yiling is a comprehensive medical institution that is part of the Yiling Group, a diversified Chinese hospital management group with more than 1300 regional service centres, providing medical plastic surgery, Traditional Chinese Medicine (TCM) outpatient clinics, and health management centres. The Centre is located in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. Medical tourism has become one of the world's fastest-growing emerging industries, and southern China's Hainan province is being developed to establish a complete healthcare tourism eco-system that provides high-end, precision medical treatment and high-quality specialty in medical beauty and health promotion services.



**Boao Yiling Life Care Center, Hainan Province, China.**

Osteopore CEO Goh Khoo Seng said; "The opportunity to gain an initial foothold in the Hainan area for Osteopore's products is an exciting first step. The region is currently going through significant growth in medical treatment, medical cosmetology, rehabilitation and health promotion. Their flexible policies and regulatory models allow for innovate products like ours to be trialled, and provides a base in China to enhance market penetration once regulatory approval is obtained"

For more information please contact:

**Geoff Pocock**

Osteopore Limited

+61 4 1219 4373

geoff\_pocock@osteopore.com

**About Osteopore Limited**

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent protected scaffolds are made from proprietary polymer formulations, that naturally dissolve overtime to leave only natural, healthy bone tissue, significantly reducing post-surgery complications that are commonly associated with permanent bone implants.

### **Forward Looking Statements**

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of Osteopore Limited, are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.